DIAGNOSTIC-IMAGING

DIAGNOSTIC-IMAGING

Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III trial in patients with recurrence of prostate cancer

A Step Forward in Diagnosing Prostate Cancer The United States Food and Drug Administration (FDA) has provided positive guidance on a pivotal Phase III trial for 64CuSARbisPSMA, a novel diagnostic imaging agent designed to detect prostate cancer lesions with high accuracy..

DIAGNOSTIC-IMAGING

Telix spins off radiopharma unit to form Rhine Pharma | Pharmaceutical | The Pharmaletter

Melbourne, Australiabased Telix Pharmaceuticals has made a significant move in the pharmaceutical industry by launching Rhine Pharma, a subsidiary dedicated to enhancing global access to radiopharmace..